Research Library › Mitochondrial & Coenzyme
SS-31, also called elamipretide, is a synthetic four-amino-acid peptide from the Szeto-Schiller (SS) series, co-designed by Hazel Szeto of Weill Cornell Medical College and Peter Schiller of the Montreal Clinical Research Institute and first described in a mitochondria paper in 2004. It was designed to bind cardiolipin in the inner mitochondrial membrane. As of 22 Oct 2026, elamipretide holds a 2025 FDA accelerated approval as the prescription drug Forzinity for Barth syndrome only.
Key facts
| Type | Synthetic tetrapeptide (four amino acids) |
|---|---|
| Sequence | D-Arg-Dmt-Lys-Phe-NH2 (Dmt = 2',6'-dimethyltyrosine) |
| First described | 2004, Journal of Biological Chemistry |
| Developed by | Hazel Szeto (Weill Cornell) and Peter Schiller (IRCM, Montreal) |
| Designed target | Cardiolipin in the inner mitochondrial membrane |
| Regulatory status (Oct 2026) | FDA accelerated approval (Forzinity, Sept 2025) for Barth syndrome only; not approved for any other use |
Who developed it
SS-31 belongs to a family of small peptides named after their two designers: pharmacologist Hazel Szeto of Weill Cornell Medical College in New York and peptide chemist Peter Schiller of the Institut de recherches cliniques de Montréal (IRCM). The first SS peptides were synthesized in Schiller’s Montreal laboratory [1, 2].
In 2006 Szeto founded Stealth Peptides to develop the series. The company later operated as Stealth BioTherapeutics and, in June 2026, renamed itself Mighty Therapeutics [3, 4].
Structure and designed target
SS-31 is not a copy of any natural molecule. It is a laboratory-built chain of four residues: D-arginine, 2′,6′-dimethyltyrosine (Dmt), lysine and phenylalanine, with an amidated C-terminus. It alternates aromatic and positively charged residues, a pattern the designers chose so the peptide could cross cell membranes [5, 6].
In the 2004 study that introduced the series’ mitochondrial work, the team reported that the dimethyltyrosine residue was required for the activity they measured in cell assays; analogs lacking it behaved differently [6]. The approved drug’s labeling describes elamipretide as associating with cardiolipin, a phospholipid found in the inner mitochondrial membrane, which is the proposed mechanism [5].
Why it was created
The SS peptides grew out of opioid research. While studying painkiller-like peptides, Szeto noticed one compound concentrated in mitochondria. She and Schiller then designed variants without opioid-receptor activity [3].
The resulting compound, under the name Bendavia, was first investigated in a research program on cardiac ischemia-reperfusion injury and reached human trials in that setting. Development later shifted to rare mitochondrial disease, specifically Barth syndrome, a genetic disorder affecting roughly 150 people in the United States [3, 7].
Research timeline
- 2004: First paper on the SS peptides’ mitochondrial targeting published by Szeto, Schiller and colleagues [6]
- 2006: Stealth Peptides founded [3]
- 2011: Szeto and Schiller publish a review of the series from discovery to clinical development [2]
- 2019: FDA declines the company’s first application in Barth syndrome [7]
- 19 Sep 2025: FDA grants accelerated approval to elamipretide as Forzinity [8]
- Jun 2026: Stealth renames itself Mighty Therapeutics [4]
- Jul 2026: Required confirmatory study begins [9]
Regulatory status as of October 2026
As of 22 Oct 2026, elamipretide is approved in the United States under FDA’s accelerated approval pathway as Forzinity, a prescription drug for an indication related to Barth syndrome. The approval followed a 2019 rejection and a second negative decision in 2025, and accelerated approval requires a confirmatory trial; that 72-week study began in July 2026 [7, 8, 9].
The approval covers Forzinity only. It does not extend to any other indication, and research-grade SS-31 is a separate material that is not an FDA-approved drug. SS-31 is not named on the World Anti-Doping Agency’s 2026 Prohibited List [10].
Available from Kalibra Labs
Supplied as a lyophilized research material with a Certificate of Analysis matched to each lot number.
Frequently asked questions
Who invented SS-31?
SS-31 was co-designed by Hazel Szeto of Weill Cornell Medical College and Peter Schiller of the IRCM in Montreal; the ‘SS’ stands for Szeto-Schiller.
Is SS-31 the same as elamipretide?
Yes. Elamipretide is the international nonproprietary name for SS-31, and Forzinity is the brand name of the FDA-approved drug product.
Is SS-31 FDA approved?
Elamipretide received FDA accelerated approval in September 2025 as Forzinity, for Barth syndrome only. Research-grade SS-31 is not an FDA-approved drug.
What does SS-31 bind to?
It was designed to associate with cardiolipin, a phospholipid in the inner mitochondrial membrane, according to the drug’s labeling.
What was Bendavia?
Bendavia was an earlier development name for elamipretide, used when it was investigated in a research program on cardiac ischemia-reperfusion injury.
Sources
- Institut de recherches cliniques de Montréal (IRCM). Peter W. Schiller, researcher profile. Link
- Szeto HH, Schiller PW. Novel therapies targeting inner mitochondrial membrane: from discovery to clinical development. Pharm Res. 2011;28(11):2669-2679. doi:10.1007/s11095-011-0476-8. PMID 21638136. Link
- Gold L. Pharmacologist Szeto pioneers tiny compounds with big potential. Cornell Chronicle, 4 May 2011. Link
- Mighty Therapeutics (formerly Stealth BioTherapeutics) announces new name. Press release (PRNewswire), Needham, MA, 16 Jun 2026. Link
- Forzinity (elamipretide) injection, prescribing information: sections 11 and 12.1. Reproduced at MedLibrary.org. Link
- Zhao K, Zhao GM, Wu D, Soong Y, Birk AV, Schiller PW, Szeto HH. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J Biol Chem. 2004;279(33):34682-34690. doi:10.1074/jbc.M402999200. PMID 15178689. Link
- pharmaphorum. Stealth's patience rewarded as FDA approves Barth drug. 22 Sep 2025. Link
- U.S. FDA. FDA grants accelerated approval to first treatment for Barth syndrome (Forzinity, elamipretide). Press announcement, 19 Sep 2025. Link
- Mighty Therapeutics announces first patient dosed in Phase 4 confirmatory study of elamipretide in Barth syndrome (4TAZPower). Press release, 8 Jul 2026. Link
- World Anti-Doping Agency. 2026 Prohibited List. Link
Regulatory information current as of October 2026. Reviewed by the Kalibra Labs editorial team.
For Research Use Only. Kalibra Labs supplies this compound as a lyophilized research material for in-vitro laboratory use. It is not for human or veterinary use and not for use in diagnostic or therapeutic procedures. This page is a scientific and historical reference; it is not medical advice and makes no claim about use in people or animals.
